3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vomiting
5
Neoplasms
3
Nausea
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Sarcoma
1
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Interventions
Paclitaxel
4
Carboplatin
4
Pemetrexed
2
Palliative Care
2
Gemcitabine
2
temsirolimus
1
rucaparib
1
pembrolizumab
1
niraparib
1
nintedanib
1
nilotinib
1
liposomal doxorubicin
1
fosaprepitant
1
atezolizumab
1
argatroban
1
Topotecan
1
Thrombopoietin
1
Palonosetron
1
Ocoxin
1
Laparoscopy
1
Heparin, Low-Molecular-Weight
1
Filgrastim
1
Electrocardiography
1
Educational Status
1
Dexamethasone
1
Darbepoetin alfa
1
Cognitive Behavioral Therapy
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Genital Neoplasms, Female
×
fosaprepitant
×
Clear all
NCT01074697
2015-04-24
GAND-emesis
Odense University Hospital
Phase 3
Completed
246 enrolled